20 research outputs found
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed. Patients and Methods: Eligible patients had received â„ 1 line of treatment and were administered bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for 8 cycles with or without daratumumab (16 mg/kg) until disease progression. Results: Of 498 patients in the intent-to-treat (ITT) population (D-Vd, n = 251; Vd, n = 247), 47% had 1 prior line of treatment (1PL; D-Vd, n = 122; Vd, n = 113). Median progression-free survival (PFS) was significantly prolonged with D-Vd versus Vd in the ITT population (16.7 vs. 7.1 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.25-0.40; P < .0001) and the 1PL subgroup (27.0 vs. 7.9 months; HR, 0.22; 95% CI, 0.15-0.32; P < .0001). In lenalidomide-refractory patients, the median PFS was 7.8 versus 4.9 months (HR, 0.44; 95% CI, 0.28-0.68; P = .0002) for D-Vd (n = 60) versus Vd (n = 81). Minimal residual disease (MRD)ânegativity rates (10â5) were greater with D-Vd versus Vd (ITT: 14% vs. 2%; 1PL: 20% vs. 3%; both P < .0001). PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001). No new safety concerns were observed. Conclusion: After 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates.CASTOR showed the significant clinical benefit of daratumumab plus bortezomib and dexamethasone for patients with previously treated multiple myeloma. With âŒ3 years median follow-up, this regimen continues to demonstrate significantly improved progression-free survival with higher minimal residual dis
Daratumumab plus lenalidomide and dexamethasone in relapsed/ refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are presented. Patients (Nâ=â569) with â„1 prior line received Rd (lenalidomide, 25âmg, on Days 1â21 of each 28-day cycle; dexamethasone, 40âmg, weekly)â±âdaratumumab at the approved dosing schedule. Minimal residual disease (MRD) was assessed by next-generation sequencing. After 44.3 months median follow-up, D-Rd prolonged progression-free survival (PFS) in the intent-to-treat population (median 44.5 vs 17.5 months; HR, 0.44; 95% CI, 0.35â0.55; Pâ<â0.0001) and in patient subgroups. D-Rd demonstrated higher ORR (92.9 vs 76.4%; Pâ<â0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; Pâ<â0.0001) and MRD negativity (10â5; 30.4 vs 5.3%; Pâ<â0.0001). Median time to next therapy was prolonged with D-Rd (50.6 vs 23.1 months; HR, 0.39; 95% CI, 0.31â0.50; Pâ<â0.0001). Median PFS on subsequent line of therapy (PFS2) was not reached with D-Rd versus 31.7 months with Rd (HR, 0.53; 95% CI, 0.42â0.68; Pâ<â0.0001). No new safety concerns were reported. These data support using D-Rd in patients with RRMM after first relapse
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
This study aimed to predict long-term progression-free survival (PFS) using early M-protein dynamic measurements in patients with relapsed/refractory multiple myeloma (MM). The PFS was modeled based on dynamic M-protein data from two phase III studies, POLLUX and CASTOR, which included 569 and 498 patients with relapsed/refractory MM, respectively. Both studies compared active controls (lenalidomide and dexamethasone, and bortezomib and dexamethasone, respectively) alone vs. in combination with daratumumab. Three M-protein dynamic features from the longitudinal M-protein data were evaluated up to different time cutoffs (1, 2, 3, and 6Â months). The abilities of early M-protein dynamic measurements to predict the PFS were evaluated using Cox proportional hazards survival models. Both univariate and multivariable analyses suggest that maximum reduction of M-protein (i.e., depth of response) was the most predictive of PFS. Despite the statistical significance, the baseline covariates provided very limited predictive value regarding the treatment effect of daratumumab. However, M-protein dynamic features obtained within the first 2Â months reasonably predicted PFS and the associated treatment effect of daratumumab. Specifically, the areas under the time-varying receiver operating characteristic curves for the model with the first 2Â months of M-protein dynamic data were ~Â 0.8 and 0.85 for POLLUX and CASTOR, respectively. Early M-protein data within the first 2Â months can provide a prospective and reasonable prediction of future long-term clinical benefit for patients with MM
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization/karyotyping; patients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10â5) was assessed via the clonoSEQÂź assay V2.0. 569 patients were randomized (D-Rd, nâ=â286; Rd, nâ=â283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; Pâ<â0.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; Pâ=â0.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM
was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition
of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to
develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable
analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR:
2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This
translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for
intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2â3 factors). Addition of cytogenetic abnormalities
(t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1,
intermediate risk with 2, and high risk with â„3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years,
respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical
research and routine practice and will be widely applicable
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
This study aimed to predict long-term progression-free survival (PFS) using early M-protein dynamic measurements in patients with relapsed/refractory multiple myeloma (MM). The PFS was modeled based on dynamic M-protein data from two phase III studies, POLLUX and CASTOR, which included 569 and 498 patients with relapsed/refractory MM, respectively. Both studies compared active controls (lenalidomide and dexamethasone, and bortezomib and dexamethasone, respectively) alone vs. in combination with daratumumab. Three M-protein dynamic features from the longitudinal M-protein data were evaluated up to different time cutoffs (1, 2, 3, and 6 months). The abilities of early M-protein dynamic measurements to predict the PFS were evaluated using Cox proportional hazards survival models. Both univariate and multivariable analyses suggest that maximum reduction of M-protein (i.e., depth of response) was the most predictive of PFS. Despite the statistical significance, the baseline covariates provided very limited predictive value regarding the treatment effect of daratumumab. However, M-protein dynamic features obtained within the first 2 months reasonably predicted PFS and the associated treatment effect of daratumumab. Specifically, the areas under the time-varying receiver operating characteristic curves for the model with the first 2 months of M-protein dynamic data were ~ 0.8 and 0.85 for POLLUX and CASTOR, respectively. Early M-protein data within the first 2 months can provide a prospective and reasonable prediction of future long-term clinical benefit for patients with MM. © 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
© The Author(s) 2020.Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2âg/dL (HR: 2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2â3 factors). Addition of cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1, intermediate risk with 2, and high risk with â„3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years, respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical research and routine practice and will be widely applicable.The data collection study was conducted by the International Myeloma Foundation as an International Myeloma Working Group project supported in part by a grant funded by Janssen
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of
daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone
in relapsed/refractory multiple myeloma. Efficacy and safety of
daratumumab was analyzed according to age groups of 65 to 74 years and
>= 75 years. Patients received >= 1 prior line of therapy. In POLLUX,
patients received lenalidomide/dexamethasone +/- daratumumab (16 mg/kg
weekly, cycles 1-2; every two weeks, cycles 3-6; monthly until
progression). In CASTOR, patients received eight cycles of
bortezomib/dexamethasone +/- daratumumab (16 mg/kg weekly, cycles 1-3;
every three weeks, cycles 4-8; monthly until progression). Patients aged
>75 years received dexamethasone 20 mg weekly. For patients aged >= 75
years in POLLUX (median follow-up: 25.4 months),
daratumumab/lenalidomide/dexamethasone prolonged progression-free
survival versus lenalidomide/dexamethasone (median: 28.9 versus 11.4
months; hazard ratio, 0.27; 95% confidence interval, 0.10-0.69;
P=0.0042) and increased overall response rate (93.1% versus 76.5%;
P=0.0740). Neutropenia was the most common grade 3/4 treatment-emergent
adverse event (daratumumab: 44.8%; control: 31.4%). Infusion-related
reactions occurred in 12 (41.4%) patients. For patients aged >= 75
years in CASTOR (median follow-up: 19.4 months),
daratumumab/bortezomib/dexamethasone prolonged progression-free survival
versus bortezomib/dexamethasone (median: 17.9 versus 8.1 months; hazard
ratio, 0.26; 95% confidence interval, 0.10-0.65; P=0.0022) and
increased overall response rate (95.0% versus 78.8%; P=0.1134).
Thrombocytopenia was the most common grade 3/4 treatment-emergent
adverse event (daratumumab: 45.0%; control: 37.1%). Infusion-related
reactions occurred in 13 (65.0%) patients. Similar findings were
reported for patients aged 65 to 74 years in both studies. Taken
together, this subgroup analysis of efficacy and safety of daratumumab
was largely consistent with the overall populations
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies
none19siThe phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age groups of 65 to 74 years and â„75 years. Patients received â„1 prior line of therapy. In POLLUX, patients received lenalidomide/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-2; every two weeks, cycles 3-6; monthly until progression). In CASTOR, patients received eight cycles of bortezomib/dexamethasone ± daratumumab (16 mg/kg weekly, cycles 1-3; every three weeks, cycles 4-8; monthly until progression). Patients aged >75 years received dexamethasone 20 mg weekly. For patients aged â„75 years in POLLUX (median follow-up: 25.4 months), daratumumab/lenalido-mide/dexamethasone prolonged progression-free survival versus lenalido-mide/dexamethasone (median: 28.9 versus 11.4 months; hazard ratio, 0.27; 95% confidence interval, 0.10-0.69; P=0.0042) and increased overall response rate (93.1% versus 76.5%; P=0.0740). Neutropenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 44.8%; control: 31.4%). Infusion-related reactions occurred in 12 (41.4%) patients. For patients aged â„75 years in CASTOR (median follow-up: 19.4 months), daratumumab/bortezomib/dexamethasone prolonged progression-free survival versus bortezomib/dexamethasone (median: 17.9 versus 8.1 months; hazard ratio, 0.26; 95% confidence interval, 0.10-0.65; P=0.0022) and increased overall response rate (95.0% versus 78.8%; P=0.1134). Thrombocytopenia was the most common grade 3/4 treatment-emergent adverse event (daratumumab: 45.0%; control: 37.1%). Infusion-related reactions occurred in 13 (65.0%) patients. Similar findings were reported for patients aged 65 to 74 years in both studies. Taken together, this subgroup analysis of efficacy and safety of daratumumab was largely consistent with the overall populations.noneMateos, Maria-Victoria; Spencer, Andrew; Nooka, Ajay K; Pour, Ludek; Weisel, Katja; Cavo, Michele; Laubach, Jacob P; Cook, Gordon; Iida, Shinsuke; Benboubker, Lotfi; Usmani, Saad Z; Yoon, Sung-Soo; Bahlis, Nizar J; Chiu, Christopher; Ukropec, Jon; Schecter, Jordan M; Qin, Xiang; O'Rourke, Lisa; Dimopoulos, Meletios AMateos, Maria-Victoria; Spencer, Andrew; Nooka, Ajay K; Pour, Ludek; Weisel, Katja; Cavo, Michele; Laubach, Jacob P; Cook, Gordon; Iida, Shinsuke; Benboubker, Lotfi; Usmani, Saad Z; Yoon, Sung-Soo; Bahlis, Nizar J; Chiu, Christopher; Ukropec, Jon; Schecter, Jordan M; Qin, Xiang; O'Rourke, Lisa; Dimopoulos, Meletios